Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetic testing of tacrolimus using MDR-1 genotyping in kidney transplant recipients
2006-005774-50Phase 4Terminated
- Sponsor
- Central Manchester University Hospitals NHS Foundation Trust
- Start
- Dec 2006
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in kidney allograft rejection and immunocompromise, sponsored by Central Manchester University Hospitals NHS Foundation Trust. Primary endpoint: MDR-1 genotype distribution and its relation to tacrolimus dosing category. Started Dec 2006; status: terminated.
02
Drugs
tacrolimus
03
Conditions
kidney allograft rejectionimmunocompromise
Beyond the preview
Go deeper on 2006-005774-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005774-50.